Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
暂无分享,去创建一个
P. Riedell | M. Perales | D. Porter | S. Devlin | M. Bishop | S. Schuster | O. Oluwole | V. Bachanova | R. Maziarz | J. Flynn | L. Nastoupil | K. Wudhikarn | Ana Alarcon Tomas | Jamie Brower | J. Mcguirk | A. Alarcon Tomas | J. Flynn
[1] P. Riedell,et al. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas. , 2022, Transplantation and cellular therapy.
[2] R. Greil,et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. , 2021, The New England journal of medicine.
[3] D. Dingli,et al. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. , 2021 .
[4] S. Schuster,et al. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. , 2021, The New England journal of medicine.
[5] Zahra Mahmoudjafari,et al. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. , 2021, Transplantation and cellular therapy.
[6] D. Miklos,et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.
[7] Michael L. Wang,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.
[8] Y. Balagurunathan,et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.
[9] J. Vose,et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Bar,et al. Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] H. Holte,et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. , 2019, Blood advances.
[12] D. Maloney,et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.
[13] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[15] S. Grupp,et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. , 2017, Blood.
[16] A. Zelenetz,et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.
[17] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Vanessa M. Hubbard-Lucey,et al. Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent , 2013, PloS one.
[19] A. LaCasce,et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era , 2013, British journal of haematology.
[20] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.